Dermatologicals
Refine Search
Biotechnology
Colorado, USA-based biotech Enveda Biosciences, which is using AI to translate nature into new medicines, has announced an oversubscribed $130 million Series C funding round led by Kinnevik and FPV. 22 November 2024
Biotechnology
The landscape of atopic dermatitis (AD) treatment is advancing with approvals of oral and topical Janus kinase (JAK) inhibitors across the seven major pharmaceutical markets (7MM; USA, France, Germany, Italy, Spain, UK and Japan). 20 November 2024
Biotechnology
Johnson & Johnson and partner Protagonist Therapeutics have reported positive topline results from two Phase III studies testing a first-in-class oral peptide. 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental Biologics License Application (sBLA) for Dupixent(dupilumab), Regeneron and partner Sanofi revealed late Friday. 18 November 2024
Pharmaceutical
Danish dermatology specialist LEO Pharma today announced that Swissmedic, Switzerland’s national regulatory agency for approving and overseeing therapeutic products, has granted marketing approval for Anzupgo (delgocitinib) cream. 14 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Pharmaceutical
Almirall, the Spain-based biopharma, reported a 7.9% increase in net sales for the first nine months of 2024, reaching 728 million euros ($775 million), and an EBITDA rise of 2.9% to $152 million. 11 November 2024
Biotechnology
New research has been published in the Journal of Allergy and Clinical Immunology (JACI) that shows treatment with amlitelimab, an anti-OX40 ligand antibody, significantly reduced symptoms of atopic dermatitis (AD) and was maintained even after treatment stopped. 9 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted a Rare Pediatric disease designation for BPM31510T, an investigational treatment for epidermolysis (EB) from BPGbio. 4 November 2024
Pharmaceutical
Denmark’s privately-held dermatology specialist LEO Pharma and Japan’s Kyowa Kirin have revealed that they will terminate the distribution and co-promotion agreement for the psoriasis vulgaris treatment Dovobet Ointment, Gel, and Foam (calcipotriol hydrate / betamethasone dipropionate) in Japan on December 31, 2024. 1 November 2024
Biotechnology
Regeneron Pharmaceuticals today announced financial results for the third quarter of 2024 that beat expectations, but still saw its share price fall more than 6% to $866 in early trading. 31 October 2024
Biotechnology
Treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment, says US healthcare giant Johnson & Johnson. 25 October 2024
Biotechnology
New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with Dupixent (dupilumab). 25 October 2024
Biosimilars
Iceland-based Alvotech and the US unit of Israel’s of Teva Pharmaceutical Industries today revealed that that the US Food and Drug Administration (FDA) has approved Selarsdi (ustekinumab-aekn) in a new presentation 22 October 2024
Pharmaceutical
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
The US Food and Drug Administration (FDA) has approved a 2mL pre-filled syringe and pre-filled autoinjector, each containing 320mg of Belgian drugmaker UCB’s Bimzelx (bimekizumab-bkzx), to treat psoriasis. 14 October 2024
Biosimilars
Bio-Thera Solutions and Hungary’s Gedeon Richter have reached an exclusive commercialization and license agreement. 14 October 2024
Biotechnology
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Pharmaceutical
A new antibiotic, the first of its class, has received a positive review from the US Food and Drug Administration's (FDA) Antimicrobial Drug Discovery Committee ahead of a full FDA decision in October. 9 August 2018
Biotechnology
The USA’s Institute for Clinical and Economic Review (ICER) on Friday released a Final Condition Update report and Report-at-a-Glance on targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis. 6 August 2018
Pharmaceutical
In news last week, on the clinical trials front RedHill BioPharma attracted attention with its Phase III study of Crohn’s candidate RHB-104. There was disappointment for Sienna Biopharmaceuticals as its acne vulgar drug SNA-001 failed in a Phase III study, and Epizyme’s update on tazemetostat development for lymphoma caused some concern as the company lost 24% of its market value. Regulatory news included Progenics’ rare disease drug Azedra approval by the US Food and Drug Administration also elicited comment, as did European Union approval and pending launch of Amgen and Novartis’ migraine drug Aimovig. 5 August 2018
Pharmaceutical
Spanish drugmaker Almirall was trading 4% higher by lunchtime on Friday following news that it is to acquire the US medical dermatology portfolio of Ireland-incorporated Allergan. 3 August 2018
Biotechnology
US biotech Regeneron Pharmaceuticals posted second-quarter 2018 financials before the market opened, showing that total revenues increased 9% to $1.61 billion. 2 August 2018
Pharmaceutical
German pharma major Bayer announced on Tuesday that it intends to sell its portfolio of prescription dermatological products to LEO Pharma. 31 July 2018
Biotechnology
Shares in Californian dermatology specialist Sienna Biopharmaceuticals closed down around 5% on Monday, after the firm announced two key trials had failed to meet their primary endpoints. 31 July 2018
Pharmaceutical
For the second quarter in a row, Almirall has reported financial results that suggest that the Spanish drugmaker has put the woes of 2017 behind it. 30 July 2018
Biosimilars
Sandoz, a division of Swiss pharma titan Novartis, announced on Friday that it had received marketing authorization from the European Commission for its biosimilar equivalent of AbbVie's Humira (adalimumab). 30 July 2018
Pharmaceutical
Dermatology specialist Botanix Pharmaceuticals has named Stephane Levy its chief medical officer. 27 July 2018
Biotechnology
Swiss pharma giant Novartishas entered into an exclusive license agreement with two biotech companies – Belgo-Dutch Galapagos and Germany’s MorphoSys - regarding their atopic dermatitis compound MOR106. 19 July 2018
Pharmaceutical
Dermavant Sciences, a subsidiary of Roivant Sciences, has agreed to purchase the rights to tapinarof, an investigational therapeutic aryl hydrocarbon receptor modulating agent (TAMA) for the treatment of psoriasis and atopic dermatitis and back-up programs. 12 July 2018
Pharmaceutical
DUSA Pharmaceuticals has filed trade secret misappropriation and tortious interference claims in an ongoing patent infringement lawsuit against Germany-based skin cancer specialist Biofrontera and subsidiaries in the US District Court for the District of Massachusetts. 12 July 2018
Biotechnology
Sanofi Genzyme says that it is disappointed with the recent recommendation by the Canadian Agency for Drugs and Technologies in Health (CADTH) to not reimburse Dupixent (dupilumab), one of the most important recent pharmacological innovations for the treatment of adult patients with moderate-to-severe atopic dermatitis (AD). 10 July 2018
Pharmaceutical
In regulatory news last week, upside was seen in US drug developer Dermira beyond US Food and Drug Administration approval of its dermatological product Qbrexza. As far as deal-making was concerned, Adamis Pharma at last finding a partner for its epinephrine injector Symjepi was seen as a major success. On the research front, attracting attention were Biogen and Eisai’s Phase II success with Alzheimer’s candidate BAN2491, with both companies shares leaping around 20%, and Gemphire’ positive Phase IIb results with its NASH candidate gemcabene. Meantime, the US Institute for Clinical and Economic Review’s (ICER) largely positive view on the pricing of new migraine drug Aimovig must have been music to the ears of Amgen and Novartis. 8 July 2018
Pharmaceutical
Sinclair Pharma stock was up nearly 35% at 24.7p in early afternoon trading on Thursday following the announcement of better-than-expected financial as well as a takeover approach. 6 July 2018
Pharmaceutical
Shares in California, USA-based Dermira rose 9.73% to $10.88 a share in early trading Friday (with a 25% spike pre-market), after the company reported it had received approval from the US Food and Drug Administration for its new wipe designed to treat patients with excessive underarm sweating. 2 July 2018
Biotechnology
English patients who have not responded to at least one other systemic therapy will soon be able to receive routine National Health Service prescriptions for a targeted biologic for moderate to severe atopic dermatitis, the most common type of eczema. 22 June 2018
Biotechnology
The US Food and Drug Administration has approved Rituxan (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV). 8 June 2018
Biotechnology
The recent US Food and Drug Administration approval for Cimzia (certolizumab pegol) marks Belgian drugmaker UCB’s entrance into the immuno-dermatology market, a competitive field in which Cimzia could find a niche space. 6 June 2018
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze